NCT07255638 2026-02-10
A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany
Blueprint Medicines Corporation
Recruiting
Clinical Trials
6 trialsNCT06327685 2026-01-08
Avapritinib With Decitabine in Patients With SM-AHN
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Recruiting
NCT03731260 2025-09-23
(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis
Blueprint Medicines Corporation
Phase 2 Active not recruiting
NCT03580655 2025-04-30
(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
Blueprint Medicines Corporation
Phase 2 Completed
NCT05821738 2023-05-09
Avapritinib in CBF-AML With KIT Mutations
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT02561988 2023-03-17
(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies
Blueprint Medicines Corporation
Phase 1 Completed